Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Array Biopharma Inc    ARRY

ARRAY BIOPHARMA INC

(ARRY)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Array Biopharma : Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2019 | 07:17pm EDT
FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S.

(Reuters) - Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

The largest U.S. drugmaker agreed to pay a hefty premium of 62% for Array, which sells the combination treatment Braftovi and Mektovi for melanoma. But those drugs appear poised to become part of a promising triple combination for advanced colorectal cancer.

Pfizer executives said the company began actively pursuing Array last month after it released positive clinical data showing that Braftovi and Mektovi in combination with Eli Lilly and Co's Erbitux helped reduce the risk of death from colorectal cancer by 48% compared to the standard of care in patients with a gene mutation known as BRAF V600E.

The data "is really a landmark publication in one of the most dismal tumours," Pfizer research chief Mikael Dolsten said in a phone interview.

"There will be ample opportunities to do combinations and build a whole science platform around colorectal cancer," said Dolsten, adding that he believes the Array drugs could eventually tackle colon cancer earlier in the disease process.

That is a type of cancer where the class of immunotherapies that include Merck and Co's blockbuster Keytruda have not been as compelling as Array's results, Morningstar analyst Damien Conover said.

Braftovi and Mektovi, launched last July for the deadliest form of skin cancer at a price of $22,000 per month, had sales of around $72 million over their first nine months. The company also has revenue from royalty and licensing deals.

Pfizer is paying $48 per share for Array, which closed 57% higher. Pfizer's shares rose almost 0.3%.


(Graphic - Array biopharma shares,

Oncology has become one of the most profitable areas for drug companies as breakthroughs in treatments have improved survival rates and costs for the drugs have surged.

Array is Pfizer's first major purchase under new Chief Executive Albert Bourla, who took on the role in January. It is also its biggest acquisition since a $14 billion purchase of Medivation in 2016 gave it the prostate cancer drug Xtandi, forecast by analysts to top $1 billion in sales next year.

Bourla and his predecessor Ian Read have been saying for more than a year that the company would eschew transformative deals because of the strength of its pipeline. But in April, Pfizer said it would consider bolt-on deals worth a few billion dollars to complement its pipeline.

Read had previously failed to close megadeals to acquire rivals AstraZeneca and later Allergan.

Pfizer's growth has slowed in recent years and Bourla has been touting the company's "15 in 5" plan to launch 15 experimental treatments, each with at least $1 billion annual sales potential, over a five-year period. The company been investing in cancer drugs and gene therapies.

Pfizer said it expects to complete the deal in the second half of 2019.

The transaction is expected to add to earnings beginning 2022, and will reduce adjusted earnings per share by between 4 and 5 cents this year and in 2020, Pfizer said.

Pfizer said it expects to finance the majority of the deal, which has an enterprise value of about $11.4 billion, with debt and the remaining with existing cash.

Pfizer was advised by Guggenheim Securities and Morgan Stanley on the deal. Array's advisor was Centerview Partners.

(Reporting by Tamara Mathias in Bengaluru and Michael Erman in New York; Editing by Susan Thomas and Bill Berkrot)

By Michael Erman and Tamara Mathias

Stocks treated in this article : Array Biopharma Inc, Pfizer
Stocks mentioned in the article
ChangeLast1st jan.
ARRAY BIOPHARMA INC 0.39% 46.82 Delayed Quote.227.30%
PFIZER 0.63% 43.09 Delayed Quote.-1.90%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARRAY BIOPHARMA INC
07/08ARRAY BIOPHARMA : Announces interim analysis results
AQ
07/06ARRAY BIOPHARMA : Announces Interim Analysis Results from the BEACON CRC Trial o..
PU
06/26ARRAY BIOPHARMA : to Present Interim Analysis Results from Phase 3 BEACON CRC tr..
AQ
06/25ARRAY BIOPHARMA : to Present Interim Analysis Results from Phase 3 BEACON CRC Tr..
PU
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/18PFIZER : to Acquire Array BioPharma for $11.4B, Expanding Cancer Pipeline
AQ
06/18PFIZER : to buy cancer drug firm for $11.4bn
AQ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
06/18Pfizer Expands Cancer-Treatment Lineup -- WSJ
DJ
06/18PFIZER : Closes $10.6bn deal for array biopharma
AQ
More news
Financials (USD)
Sales 2019 274 M
EBIT 2019 -96,1 M
Net income 2019 -102 M
Finance 2019 74,9 M
Yield 2019 -
P/E ratio 2019 -95,7x
P/E ratio 2020 -99,1x
EV / Sales2019 37,9x
EV / Sales2020 28,0x
Capitalization 10 445 M
Chart ARRAY BIOPHARMA INC
Duration : Period :
Array Biopharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARRAY BIOPHARMA INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 45,40  $
Last Close Price 46,82  $
Spread / Highest target 2,52%
Spread / Average Target -3,03%
Spread / Lowest Target -31,7%
EPS Revisions
Managers
NameTitle
Ron Squarer Chief Executive Officer & Director
Carrie Smith Cox Chairman
Andrew R. Robbins Chief Operating Officer
Jason Haddock CFO & Principal Accounting Officer
Nicholas A. Saccomano Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARRAY BIOPHARMA INC227.30%10 445
GILEAD SCIENCES6.16%82 537
VERTEX PHARMACEUTICALS5.75%44 586
REGENERON PHARMACEUTICALS-17.20%32 370
SAREPTA THERAPEUTICS INC32.61%10 732
NEUROCRINE BIOSCIENCES, INC.20.03%7 926